Previous 10 | Next 10 |
This marks the first ex-China regulatory filing for tislelizumab, following approval in five indications in China The accepted BLA, filed in collaboration with Novartis, is supported by the positive global Phase 3 RATIONALE 302 trial in patients with previously treated, advanc...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that clinical results and subgroup analyses from the Company’s robust lung cancer program will be presented at t...
Shares of BeiGene (NASDAQ: BGNE) were soaring 17.9% higher this week as of the market close on Thursday. The big gain came after the U.S. Food and Drug Administration (FDA) approved Brukinsa as a treatment for Waldenström's macroglobulinemia (WM), a rare type of blood cancer. ...
With Labor Day marking the unofficial end of summer, September looks to be a busy month for events impacting pharmaceutical and biotechnology companies. Here's a look at what events to look forward to this month that could impact pharma and biotech stocks. Sept. 3: FDA Cellular, Tissue,...
This marks the second FDA approval for BRUKINSA and its third approval in Waldenström’s macroglobulinemia globally The approval is based on Phase 3 ASPEN trial comparing BRUKINSA against ibrutinib BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global bi...
Hutchmed (NASDAQ:HCM) has initiated a Phase Ib/II study of fruquintinib in combination with BeiGene’s (NASDAQ:BGNE) tislelizumab in patients with advanced triple negative breast cancer (TNBC) or advanced endometrial cancer (EC) in U.S. This trial is to explore the potential for the add...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a global biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted a s...
You can read full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Market watchers will be locked in on the Federal Reserve Bank of Kansas City's annual Economic Policy Symposium as the h...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
News, Short Squeeze, Breakout and More Instantly...
$800 million investment in New Jersey supports global growth and expansion with technologically advanced manufacturing capacity and clinical development capabilities for novel cancer medicines BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today ann...
2024-07-20 02:44:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
BeiGene , Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company, today announced the appointment of Aaron Rosenberg as Chief Financial Officer, effective July 22. Mr. Rosenberg will succeed Julia Wang, who is departing to pursue external opportunities and will stay with the C...